Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Rating of "Moderate Buy" from Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $209.00.

KRYS has been the subject of a number of analyst reports. Citigroup restated a "neutral" rating and issued a $166.00 price target (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. HC Wainwright reissued a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a report on Friday, August 22nd. Bank of America lowered their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Finally, Chardan Capital cut their price target on shares of Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a research note on Friday, August 22nd.

Krystal Biotech Price Performance

KRYS stock traded down $0.68 during midday trading on Monday, hitting $143.68. The company's stock had a trading volume of 350,777 shares, compared to its average volume of 250,236. The company's fifty day moving average price is $146.81 and its 200 day moving average price is $152.74. Krystal Biotech has a twelve month low of $122.80 and a twelve month high of $207.84. The stock has a market capitalization of $4.16 billion, a P/E ratio of 29.20 and a beta of 0.66.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $1.29 EPS for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. The company had revenue of $96.04 million during the quarter, compared to the consensus estimate of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. Equities analysts expect that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 1,389 shares of Krystal Biotech stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the completion of the transaction, the insider owned 1,508,056 shares in the company, valued at approximately $226,208,400. This trade represents a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last three months, insiders have sold 49,800 shares of company stock valued at $7,487,943. Company insiders own 13.70% of the company's stock.

Hedge Funds Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Brooklyn Investment Group increased its stake in shares of Krystal Biotech by 291.7% during the first quarter. Brooklyn Investment Group now owns 141 shares of the company's stock worth $25,000 after purchasing an additional 105 shares during the period. Hantz Financial Services Inc. grew its holdings in Krystal Biotech by 8,950.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 181 shares of the company's stock valued at $25,000 after buying an additional 179 shares in the last quarter. Twin Tree Management LP acquired a new position in Krystal Biotech in the 1st quarter valued at $29,000. Fifth Third Bancorp increased its position in Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after buying an additional 105 shares during the period. Finally, First Horizon Advisors Inc. lifted its holdings in shares of Krystal Biotech by 212.8% during the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company's stock worth $34,000 after buying an additional 166 shares in the last quarter. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).